One of the most frequent uses of magnetic resonance imaging (MRI) since its introduction has been in the assessment of the CNS for neoplasm. In recent years there has been a substantial improvement in the MR protocol for tumors that includes the use of functional imaging techniques. As shown in multiple experimental and clinical studies an optimized use of high quality contrast media and the introduction of these functional MRI methods has improved the detection and delineation of CNS tumors. This results not only in more confident diagnoses, but also in a substantially improved differential diagnostic process. The article reviews and summarizes the technical advances in functional techniques and their impact on the assessment of cerebral pathologies, namely brain tumors, and gives practical information on how to optimize sequence parameters to achieve the optimal tissue and pathology contrast.
Brant-ZawadskiMNormanDNewtonTH. Magnetic resonance imaging of the brain: The optimal screening technique. Radiology.1984; 152: 71–77.
2.
MuroffLRRungeVM. The use of MR contrast in neoplastic disease of the brain. Top Magn Reson Imaging.1995; 7: 137–157.
3.
EdelmannRRHesselinkJRZlatkinMB. Clinical Magnetic Resonance Imaging. Second Edition. Philadelphia: W.B. Saunders; 1996.
4.
EssigMKnoppMVSchoenbergSO. Contrast enhanced fast fluid-attenuated inversion-recovery (FLAIR) MR imaging in the assessment of primary glial tumors and brain metastases. Radiology.1999; 210: 551–557.
5.
EssigMWeberMAvon Tengg-KobligkH. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: Agents, mechanisms, and applications. Top Magn Reson Imaging.2006; 17(2): 89–106.
6.
RohrerMBauerHMintorovitchJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol.2005; 40: 715–724.
7.
PintaskeJMartirosianPGrafH. Relaxivity of gadopentetate dimeglumine (Magnevist®), gadobutrol (Gadovist®) and gadobenate dimeglumine (Multi-Hance®) in human blood plasma at 0.2 T, 1.5 T and 3 T. Invest Radiol.2006; 41: 213–221.
8.
YuhWTCFisherDJEngelkenJD. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology.1991; 180: 485–491.
9.
MyhrGRinckPABørsethA. Gadodiamide injection and gadopentetate dimeglumine: A double-blind study in MR imaging of the CNS. Acta Radiologica.1992; 33: 405–409.
10.
ValkJAlgraPRHazenbergCJ. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology.1993; 35: 173–177.
11.
OudkerkMSijensPEvan BeekEJ. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol.1995; 30: 75–78.
12.
GrecoAParkerJRRatcliffeCG. Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol.2001; 45: 457–463.
13.
AttenbergerUIRungeVMJacksonCB. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol.2009; 44: 251–260.
14.
AkesonPLarssonEMKristoffersenDT. Brain metastases – comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol.1995; 36: 300–306.
15.
YuhWTCEngelskenJDMuhonenMG. Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. Am J Neuroradiol.1992; 13: 335–345.
16.
YuhWTCFisherDJRungeVM. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. Am J Neuroradiol.1994; 15: 1037–1051.
17.
SzeGJohnsonCKawamuraY. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. Am J Neuroradiol.1998; 19: 821–828.
18.
RungeVMKirschJEBurkeVJ. High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging.1992; 2: 9–18.
19.
RungeVMWellsJWNelsonKL. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging.1994; 4: 669–673.
20.
YuhWTCTaliETNguyenHD. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. Am J Neuroradiol.1995; 16: 373–380.
21.
Van DijkPSijensPESchmitzPI. Gd-enhanced MR imaging of brain metastases: Contrast as a function of dose and lesion size. Magn Reson Imaging.1997; 15: 535–541.
22.
HausteinJLaniadoMNiendorfHP. Triple-dose ersus standard-dose gadopentetate dimeglumine: A randomized study in 199 patients. Radiology.1993; 186: 855–860.
23.
EricksonBJCampeauNGSchreinerSA. Triple-dose contrast/magnetization transfer suppressed imaging of ‘non-enhancing’ brain gliomas. J Neurooncol.2002; 60: 25–29.
24.
Peretti-VitonPTaiebDVitonJM. Contrast-enhanced magnetisation transfer MRI in metastatic lesions of the brain. Neuroradiology.1998; 40: 783–787.
25.
CavagnaFMMaggioniFCastelliPM. Gd chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol.1997; 32: 780–796.
26.
GieselFLvon Tengg-KobligkHWilkinsonID. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol.2006; 41: 222–228.
27.
KnoppMVRungeVMEssigM. Primary and secondary brain tumors at MR imaging: Bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology.2004; 230: 55–64.
28.
ColosimoCKnoppMVBarreauX. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology.2004; 46: 655–665.
29.
EssigMTartaroATartaglioneT. Enhancing lesions of the brain: Intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Academic Radiology.2006; 13: 744–751.
30.
MaravillaKRMaldjianJASchmalfussIM. Contrast enhancement of central nervous system lesions: Multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology.2006; 240: 389–400.
31.
EssigMLodemannKPLe-HuuM. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5T. Invest Radiol.2006; 41: 249–263.
32.
RollinNGuyotatJStreichenbergerN. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology.2006; 48: 150–159.
33.
KanalE. MR sequence customization for signal and contrast to noise ratio (SNR and CNR) optimization in contrast-enhanced MR imaging with higher relaxivity MR contrast agents. Presented at RSNA 2005. Book of abstracts. P794 (Abstract 2395CE-e).
34.
ChaSYangLJohnsonG. Comparison of microvascular permeability measurements, ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. Am J Neuroradiol.2006; 27: 409–417.
35.
LacerdaSLawM. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am.2009; 19: 527–557.
36.
LawMYoungRJBabbJS. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR Imaging. Radiology.2008; 247: 490–498.
37.
LawM. MR spectroscopy of brain tumors. Top Magn Reson Imaging.2004; 15: 291–313.
38.
RungeVMBiswasJWinterspergerBJ. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: Comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol.2006; 41: 224–248.
39.
BiswasJNelsonCBRungeVM. Brain tumor enhancement in magnetic resonance imaging: Comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol.2005; 40: 792–797.
40.
KnauthMWirthCRArasN. Low-field interventional MRI in neurosurgery: Finding the right dose of contrast medium. Neuroradiol.2001; 43: 254–258.
41.
RinckPAMullerRN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol.1999; 9: 998–1004.
42.
MeyerandMEPipesJMMamourianA. Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. Am J Neuroradiol.1999; 20: 117–123.
43.
LawMYangSWangH. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol.2003; 24: 1989–1998.
44.
DelormeSWeberMA. Applications of MRS in the evaluation of focal malignant brain lesions. Cancer Imaging.2006; 22: 95–99.
HartmannMHeilandSHartingI. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett.2003; 338 (2): 119–122.
47.
WeberMAZoubaaSSchlieterM. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology.2006; 66 (12): 1899–1906.
ToftsPSKermodeAG. Measu rement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med.1991; 17 (2): 357–367.
50.
PadhaniARHusbandJE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol.2001; 5 6(8): 607–620.
51.
ChoykePLDwyerAJKnoppMV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging.2003; 17 (5): 509–520.
52.
de LussanetQGLangereisSBeets-TanRG. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology.2005; 235 (1): 65–72.
53.
StieltjesBSchluterMDidingerB. Diffusion tensor imaging in primary brain tumors: Reproducible quantitative analysis of corpus callosum infiltration and contralateral involvement using a probabilistic mixture model. Neuroimage.2006; 31 (2): 531–542.
54.
ChenSIkawaFKurisuK. Quantitative MR evaluation of intracranial epidermoid tumors by fast fluid-attenuated inversion recovery imaging and echo-planar diffusion-weighted imaging. Am J Neuroradiol.2001; 22: 1089–1096.
55.
LuSAhnDJohnsonG. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: Introduction of the tumor infiltration index. Radiology.2004; 232 (1): 221–228.
